PTGES Antibody

What is PTGES and what are its alternative names in the scientific literature?

PTGES (Prostaglandin E Synthase) is a glutathione-dependent enzyme that catalyzes the conversion of prostaglandin H2 to prostaglandin E2. In the scientific literature, PTGES is also referred to by several alternative names including mPGES-1, PGES, MGST-IV, MGST1-L1, MGST1L1, and MGST1-like 1. The protein has a molecular weight of approximately 17.1 kilodaltons and belongs to the MAPEG (Membrane-Associated Proteins in Eicosanoid and Glutathione metabolism) family . When conducting literature searches or database queries, researchers should include these alternative names to ensure comprehensive results for experimental planning and comparative analysis.

What species reactivity should be considered when selecting PTGES antibodies?

When selecting PTGES antibodies for research applications, species reactivity is a critical consideration that depends on your experimental model. Based on current commercial offerings, PTGES antibodies demonstrate reactivity across several species, most commonly human, mouse, and rat models . Researchers should verify cross-reactivity through sequence homology analysis and validation studies. For non-standard research models (canine, porcine, monkey), fewer validated antibodies exist, necessitating preliminary validation experiments. When working with transgenic models, particularly knock-in or humanized models, ensure the antibody epitope region is preserved in your experimental system to prevent false negative results .

How can researchers validate the specificity of PTGES antibodies in their experimental systems?

Validating PTGES antibody specificity requires a multi-method approach to eliminate false positive/negative results. Begin with positive and negative controls: use cell lines with known PTGES expression levels (e.g., IL-1β-stimulated cells as positive controls) and PTGES-knockout cells generated via CRISPR/Cas9 as definitive negative controls . For Western blot applications, verify the detected band appears at the expected 17.1 kDa molecular weight, and consider peptide competition assays to confirm binding specificity . In immunohistochemistry applications, compare staining patterns with established PTGES expression profiles in different tissues. RNA-protein correlation analysis using qRT-PCR to confirm that protein detection corresponds with gene expression levels provides additional validation. Finally, consider using multiple antibodies targeting different epitopes of PTGES to build confidence in your detection system .

What are the most effective applications for PTGES antibodies in research settings?

PTGES antibodies demonstrate effectiveness across multiple research applications with varying degrees of optimization requirements. Western blotting (WB) represents one of the most robust applications, effectively detecting the 17.1 kDa PTGES protein in denatured samples with high specificity . Immunohistochemistry on paraffin-embedded sections (IHC-p) provides valuable spatial information regarding PTGES distribution in tissue samples, particularly in tumor microenvironment studies . Immunofluorescence (IF) and immunocytochemistry (ICC) allow for subcellular localization studies, revealing PTGES's primarily microsomal distribution. For quantitative analysis, ELISA-based applications offer higher throughput potential, though they typically require more extensive validation . Less common but emerging applications include chromatin immunoprecipitation (ChIP) for studying transcriptional regulation of PTGES and proximity ligation assays for protein-protein interaction studies involving PTGES and other inflammatory mediators.

What methodological considerations should researchers address when using PTGES antibodies for Western blotting?

When using PTGES antibodies for Western blotting, several methodological considerations are critical for optimal results. Sample preparation significantly impacts detection quality - use RIPA buffer with protease inhibitors for cell lysis, and consider microsomal fractionation to enrich for PTGES as it primarily localizes to the microsomal fraction . For protein denaturation, heating samples at 95°C for 5 minutes in reducing conditions is generally effective, although some epitopes may require non-reducing conditions. Regarding gel selection, 12-15% polyacrylamide gels provide optimal resolution for the 17.1 kDa PTGES protein . For transfer conditions, PVDF membranes typically yield better results than nitrocellulose for PTGES detection. Blocking with 5% non-fat milk is sufficient for most applications, though 5% BSA may reduce background for some antibodies. Primary antibody dilutions ranging from 1:500 to 1:2000 are commonly effective, but should be empirically determined for each antibody . Include positive controls (IL-1β-stimulated cells) and negative controls (PTGES-knockout cells) to validate specificity, as described in research using CRISPR/Cas9-mediated Ptges knockout models .

How should researchers design IHC experiments using PTGES antibodies in tumor microenvironment studies?

For immunohistochemistry experiments examining PTGES in tumor microenvironments, design considerations must address both technical parameters and biological complexities. Fixation protocols significantly impact epitope accessibility - 10% neutral-buffered formalin fixation for 24 hours is standard, but shorter fixation times (6-12 hours) may better preserve PTGES epitopes . Antigen retrieval is critical; citrate buffer (pH 6.0) with heat-induced epitope retrieval typically provides optimal results for most PTGES antibodies . When selecting antibodies, consider those validated specifically for IHC-p applications, as Western blot-validated antibodies may not perform equivalently in fixed tissues .

For experimental design, include multiple tumor regions to account for heterogeneity, and analyze both tumor cells and stromal components separately, as PTGES expression in tumor-associated macrophages has distinct functional implications from expression in tumor cells themselves . Serial sections should be stained for macrophage markers (CD68, CD163), T-cell markers (CD8, CD4), and myeloid-derived suppressor cell (MDSC) markers to correlate PTGES expression with immune cell infiltration patterns . Quantification methods should include both intensity scoring (0-3+) and percentage of positive cells, with digital image analysis providing more reproducible results than manual scoring.

What is the role of PTGES/PGE2 signaling in cancer immunosuppression?

PTGES/PGE2 signaling plays a multifaceted role in cancer immunosuppression through several interconnected mechanisms. Research has demonstrated that PTGES upregulation in tumor cells significantly enhances PGE2 production, which acts as a critical mediator of immune evasion . At the cellular level, PTGES/PGE2 signaling directly impacts cytotoxic T-cell function, as evidenced by cytolytic T-cell assays showing that PTGES-knockout tumor cells become susceptible to T-cell-mediated killing, while PTGES-expressing tumor cells resist cytotoxicity .

The signaling pathway also profoundly influences the tumor microenvironment composition by promoting M2 macrophage polarization, which exhibits tumor-promoting rather than tumor-suppressing properties . Furthermore, PTGES/PGE2 signaling increases the production of cytokines and chemokines (including G-CSF, MCP-1, GM-CSF, and TNFα) that recruit myeloid-derived suppressor cells (MDSCs) to the tumor microenvironment . This recruitment has been quantitatively demonstrated, with significantly higher percentages of G-MDSCs found in experimental models with active PTGES/PGE2 signaling compared to PTGES-knockout models . The cumulative effect is a suppression of CD8+ T-cell infiltration, with research showing reduced CD8+ T-cell percentages in lungs with PTGES-expressing tumors (28.7% in wild-type mice) compared to those with PTGES-knockout tumors (36.7% in wild-type mice) .

How does PTGES expression correlate with tumor progression and metastasis?

PTGES expression demonstrates significant correlations with tumor progression and metastatic potential through multiple mechanistic pathways. Experimental evidence shows that PTGES knockout in tumor cell lines (using CRISPR/Cas9 systems) substantially reduces colony formation capacity, anchorage-independent growth, and migration/invasion potential compared to parental cell lines with intact PTGES expression . These cellular characteristics are fundamental hallmarks of metastatic capability. Additionally, PTGES expression influences cancer stem cell populations, with research demonstrating that CD44+ cells (a stem cell-enriched subpopulation) decrease dramatically from 12.5% in parental tumor cells to 1.99% in PTGES-knockdown cells .

In metastasis models, the pattern of lung metastatic nodules strongly correlates with PGE2 levels, with higher PGE2 production associated with increased metastatic burden . This correlation extends to the immunosuppressive tumor microenvironment, where PTGES/PGE2 signaling mediates the recruitment of tumor-associated macrophages (TAMs) and myeloid cells that facilitate metastatic colonization . The relationship between PTGES expression and p53 status adds another dimension to this correlation, as PTGES expression can be induced by the tumor suppressor p53, potentially contributing to p53-induced apoptosis under certain conditions while promoting tumor progression under others .

What is the relationship between PTGES and inflammatory processes in disease models?

PTGES demonstrates complex relationships with inflammatory processes across various disease models, functioning as both a product and mediator of inflammation. In inflammatory conditions, PTGES expression is rapidly induced by proinflammatory cytokines, particularly interleukin-1β (IL-1β), establishing a feed-forward inflammatory amplification loop . This induction operates primarily through NF-κB and AP-1 transcription factor pathways, linking PTGES to canonical inflammatory signaling.

The functional consequences of PTGES upregulation in disease models are context-dependent. In cancer models, PTGES-derived PGE2 promotes an immunosuppressive inflammatory environment characterized by M2 macrophage polarization and MDSC recruitment . This represents a "non-resolving inflammation" pattern that facilitates tumor progression. In contrast, in acute inflammation models, PTGES-derived PGE2 can exhibit both pro-inflammatory effects (vasodilation, increased vascular permeability) and resolution-promoting effects (switch from leukotriene to lipoxin production).

The physiological significance of PTGES in inflammation varies by tissue and disease state. In neuroinflammatory models, PTGES expression in microglia contributes to neurodegeneration. In cardiovascular disease models, PTGES in vascular smooth muscle cells and macrophages promotes atherosclerotic plaque formation. In gastrointestinal models, PTGES provides mucosal protection under physiological conditions but can promote chronic inflammation in disease states. These variable functions highlight the contextual nature of PTGES in the inflammatory continuum between homeostasis and disease.

How can researchers effectively design PTGES knockout models to study its function?

Designing effective PTGES knockout models requires strategic consideration of targeting approach, validation methods, and experimental controls. For CRISPR/Cas9-mediated knockout, target guide RNAs to early exons (particularly exons 1-2) of the PTGES gene to ensure complete functional disruption . Design at least 3-4 different gRNAs and screen for knockout efficiency, as demonstrated in successful PTGES knockout studies that completely abolished PGE2 production . For conditional knockout approaches, the Cre-loxP system with loxP sites flanking essential PTGES exons allows tissue-specific or inducible deletion, which is particularly valuable when studying tissues where PTGES may play essential developmental roles.

Comprehensive validation of PTGES knockout requires multi-level confirmation: genomic validation through sequencing the targeted region, transcriptional validation via RT-qPCR, protein validation through Western blotting with validated antibodies, and functional validation by measuring PGE2 production using ELISA or mass spectrometry . Success metrics should include >90% reduction in PGE2 levels compared to control cells.

Essential experimental controls include wild-type parental lines, clonal control lines that underwent CRISPR treatment but retained PTGES expression, and rescue experiments with exogenous PTGES to confirm phenotype specificity . For in vivo models, littermate controls are critical to minimize genetic background effects. Consider potential compensatory mechanisms, particularly upregulation of other PGE synthases (PTGES2, PTGES3) that may partially restore PGE2 production in long-term knockout models.

What strategies should be employed when investigating PTGES signaling interactions with immune cell populations?

Investigating PTGES signaling interactions with immune cell populations requires methodological approaches that capture both direct effects and microenvironmental influences. For in vitro co-culture systems, design transwell experiments that separate tumor cells (with or without PTGES expression) from immune cell populations to distinguish between contact-dependent and soluble mediator effects . Include conditions with PGE2 receptor antagonists to confirm pathway specificity, targeting the four EP receptors (EP1-4) individually and in combination.

For flow cytometric analyses of immune populations, comprehensive panels should simultaneously evaluate multiple immune cell types: use CD11b+F4/80+ markers for macrophages with additional M1/M2 discrimination (CD86/CD206), CD11b+Gr-1+ for MDSCs with further G-MDSC/M-MDSC discrimination, and CD3+CD8+ markers for cytotoxic T cells with activation markers (CD69, CD25) . Functional assays should accompany phenotypic characterization, including cytolytic assays for T cells, phagocytosis assays for macrophages, and T-cell suppression assays for MDSCs .

In vivo imaging approaches using multiplex immunofluorescence or imaging mass cytometry provide spatial context for immune-tumor interactions, revealing localization patterns that may indicate direct cellular interactions or zones of influence. Single-cell RNA sequencing of tumor-infiltrating immune cells from PTGES-positive versus PTGES-knockout tumors can identify transcriptional programs affected by PTGES signaling beyond the canonical pathways, as suggested by research showing broader cytokine and chemokine alterations in PTGES-modulated systems .

What are the emerging applications of active learning approaches for antibody-antigen binding prediction in PTGES research?

Active learning approaches represent cutting-edge methodologies for optimizing antibody-antigen binding predictions with significant implications for PTGES antibody development and application. These computational strategies address the fundamental challenge of costly experimental binding data generation by strategically selecting the most informative antibody-antigen pairs for experimental validation . For PTGES research, where multiple epitopes and antibody clones exist, active learning can reduce the number of required experimental validation steps by up to 35% while accelerating the learning process by approximately 28 steps compared to random selection approaches .

Implementation of active learning in PTGES antibody research follows a structured workflow: beginning with a small dataset of known binding interactions between various antibodies and PTGES epitopes, machine learning models predict binding affinities for untested combinations . The most informative predictions (typically those with highest uncertainty) are selected for experimental validation, and these new data points are incorporated to retrain the model iteratively . This approach is particularly valuable for out-of-distribution predictions - scenarios where new antibodies or PTGES variants (such as species orthologs or post-translationally modified forms) weren't represented in the initial training data .

Three algorithmic strategies have demonstrated particular effectiveness: uncertainty sampling (selecting predictions with highest entropy), diversity sampling (maximizing physicochemical diversity of selected pairs), and expected model change (selecting instances that would most significantly alter the model parameters) . The practical benefit for researchers is the ability to develop comprehensive binding profiles for PTGES antibodies across conditions and variants while minimizing experimental costs and accelerating development timelines.

What are common sources of false positives/negatives in PTGES antibody-based experiments?

PTGES antibody experiments face several potential sources of false results that require systematic troubleshooting. False positives commonly arise from antibody cross-reactivity with structurally similar proteins in the MAPEG family, particularly MGST1, which shares sequence homology with PTGES . Non-specific binding to highly abundant proteins can also generate misleading signals, especially in protein-rich samples. Background issues in immunohistochemistry often result from endogenous peroxidase activity or biotin, requiring appropriate blocking steps .

False negatives frequently occur due to epitope masking, particularly when the antibody recognition site is obscured by protein-protein interactions or post-translational modifications of PTGES . Sample preparation issues significantly contribute to detection failure - PTGES is membrane-associated and can be lost during processing if appropriate detergents aren't used . For formalin-fixed samples, excessive fixation can irreversibly mask epitopes, while inadequate antigen retrieval fails to expose them sufficiently .

Methodological validation strategies to address these issues include: (1) using PTGES knockout controls generated via CRISPR/Cas9 to confirm signal specificity , (2) employing multiple antibodies targeting different PTGES epitopes to verify consistent detection patterns, (3) correlating protein detection with mRNA expression, and (4) including positive controls from IL-1β-stimulated cells which upregulate PTGES expression . When inconsistent results occur between detection methods (e.g., positive IHC but negative Western blot), consider whether differential protein conformation may be affecting epitope accessibility.

How can researchers optimize PTGES antibody protocols for tissues with variable expression levels?

Optimizing PTGES antibody protocols for tissues with variable expression levels requires a systematic approach to signal amplification and background reduction. For tissues with low PTGES expression, signal amplification techniques should be strategically employed - consider tyramide signal amplification (TSA) which can increase detection sensitivity 10-100 fold over standard detection methods . Polymer-based detection systems generally provide better signal-to-noise ratios than avidin-biotin complexes for low-expression tissues.

Sample preparation modifications can significantly improve detection in challenging tissues: for frozen sections, acetone fixation often better preserves PTGES epitopes than formalin-based methods . For paraffin-embedded tissues with variable fixation histories (particularly archived samples), extended antigen retrieval (up to 40 minutes) with Tris-EDTA buffer (pH 9.0) may recover more epitopes than standard protocols .

Antibody incubation conditions should be optimized based on expression levels: for high-expression tissues, shorter incubation times (1-2 hours) at room temperature with higher antibody dilutions (1:500-1:1000) minimize background while maintaining specific signal . For low-expression tissues, extended incubation times (overnight at 4°C) with more concentrated antibody solutions (1:50-1:200) maximize sensitivity . Always include positive controls with known high PTGES expression (such as inflammatory tissue samples) alongside test tissues to confirm detection system functionality.

Digital image analysis with appropriate thresholding can help standardize interpretation across tissues with variable expression, using positive controls to establish detection parameters. When comparing across tissues with dramatically different expression levels (such as tumor versus normal tissue), consider using multiple antibody dilutions to ensure both high and low expressing regions fall within the linear detection range.

What approaches can address reproducibility challenges in PTGES antibody-based experiments?

Addressing reproducibility challenges in PTGES antibody-based experiments requires systematic protocol standardization and comprehensive reporting practices. Establish detailed standard operating procedures (SOPs) that precisely define critical parameters: for antibody dilutions, specify both concentration (μg/mL) and dilution ratio to account for stock concentration variations between lots . For antigen retrieval, document buffer composition, pH, temperature, duration, and cooling methods rather than using generic terms like "standard retrieval" .

Antibody validation represents a cornerstone of reproducibility: document lot-specific validation using positive controls (IL-1β-stimulated cells), negative controls (PTGES knockout samples), and specificity tests (peptide competition) . Whenever possible, include validation across multiple detection platforms (Western blot, IHC, IF) to confirm consistent target recognition . For longitudinal studies, purchase sufficient antibody from a single lot to complete the entire study, as lot-to-lot variations can significantly impact results.

Data management practices substantially influence reproducibility: maintain detailed electronic laboratory notebooks documenting exact experimental conditions including room temperature, incubation times, reagent sources/lots, and equipment calibration status . For quantitative analyses, blind scoring should be employed when possible, with multiple independent evaluators and clearly defined scoring criteria . Implement positive and negative staining controls in every experimental run to facilitate inter-run normalization.

For publishing PTGES antibody-based results, adhere to reporting guidelines such as those from the Global Biological Standards Institute, including RRID identifiers for antibodies, validation evidence, detailed methodological parameters, representative images of positive and negative controls, and raw unprocessed data availability statements .

Table: Comparative Analysis of PTGES Antibody Applications in Research